These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37951152)

  • 1. The role of vitamin D3 in modulating the interplay between NLRP3 inflammasome and autophagy in NASH.
    Abdelrahman BA; Hammam OA; El-Khatib AS; Attia YM
    Biochem Biophys Res Commun; 2023 Dec; 688():149122. PubMed ID: 37951152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
    Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
    Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
    Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,25(OH)
    Cao R; Ma Y; Li S; Shen D; Yang S; Wang X; Cao Y; Wang Z; Wei Y; Li S; Liu G; Zhang H; Wang Y; Ma Y
    J Leukoc Biol; 2020 Jul; 108(1):283-295. PubMed ID: 32237257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.
    Zhang NP; Liu XJ; Xie L; Shen XZ; Wu J
    Lab Invest; 2019 Jun; 99(6):749-763. PubMed ID: 30700851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
    Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
    Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yen IC; Lin JC; Chen Y; Tu QW; Lee SY
    Am J Chin Med; 2020; 48(8):1859-1874. PubMed ID: 33308101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH.
    Li H; Cao Z; Wang L; Li J; Cheng X; Tang Y; Xing M; Yao P
    J Nutr Biochem; 2023 Feb; 112():109217. PubMed ID: 36402251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
    J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ.
    Chen Y; He X; Yuan X; Hong J; Bhat O; Li G; Li PL; Guo J
    Oxid Med Cell Longev; 2018; 2018():2901871. PubMed ID: 30140364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
    Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury.
    Kim MY; Jeong B; Lee GS; Jeon H; Yang YM; Yang H; Han YH
    Int Immunopharmacol; 2024 Feb; 128():111565. PubMed ID: 38262161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.
    Csak T; Pillai A; Ganz M; Lippai D; Petrasek J; Park JK; Kodys K; Dolganiuc A; Kurt-Jones EA; Szabo G
    Liver Int; 2014 Oct; 34(9):1402-13. PubMed ID: 24650018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
    Liu J; Wang T; He K; Xu M; Gong JP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release.
    Pan J; Ou Z; Cai C; Li P; Gong J; Ruan XZ; He K
    Cell Immunol; 2018 Oct; 332():111-120. PubMed ID: 30103942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
    Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
    Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.
    Kim SH; Kim G; Han DH; Lee M; Kim I; Kim B; Kim KH; Song YM; Yoo JE; Wang HJ; Bae SH; Lee YH; Lee BW; Kang ES; Cha BS; Lee MS
    Autophagy; 2017 Oct; 13(10):1767-1781. PubMed ID: 28933629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.